J David Spence1. 1. Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, Western University, 1400 Western Road, London, ON, N6G 2V4, Canada. dspence@robarts.ca.
Abstract
PURPOSE OF REVIEW: To assess the validity of the belief that anticoagulation is not beneficial in patients with embolic stroke of unknown source (ESUS), and to asssess the benefits and safety of direct-acting oral anticoagulants (DOACs). RECENT FINDINGS: The failure of randomized trials to show benefit of anticoagulation in ESUS is probably due to misclassification of large artery atherosclerosis (LAA) as ESUS, as defined by a stenosis ≥ 50%. There are important differences among DOACs. There are a number of problems with dabigatran, and rivaroxaban and edoxaban are not suitable for once-daily dosing. Recent evidence from real-world practice indicates that apixaban is more effective and safer than rivaroxaban. Plaque burden should be included in the definition of LAA. Patients in whom a cardioembolic source is strongly suspected should be anticoagulated; antiplatelet agents are not significantly safer than DOACs, and are not effective in cardioembolic stroke.
PURPOSE OF REVIEW: To assess the validity of the belief that anticoagulation is not beneficial in patients with embolic stroke of unknown source (ESUS), and to asssess the benefits and safety of direct-acting oral anticoagulants (DOACs). RECENT FINDINGS: The failure of randomized trials to show benefit of anticoagulation in ESUS is probably due to misclassification of large artery atherosclerosis (LAA) as ESUS, as defined by a stenosis ≥ 50%. There are important differences among DOACs. There are a number of problems with dabigatran, and rivaroxaban and edoxaban are not suitable for once-daily dosing. Recent evidence from real-world practice indicates that apixaban is more effective and safer than rivaroxaban. Plaque burden should be included in the definition of LAA. Patients in whom a cardioembolic source is strongly suspected should be anticoagulated; antiplatelet agents are not significantly safer than DOACs, and are not effective in cardioembolic stroke.
Authors: J David Spence; Michael Eliasziw; Maria DiCicco; Daniel G Hackam; Ramzy Galil; Tara Lohmann Journal: Stroke Date: 2002-12 Impact factor: 7.914
Authors: Hans-Christoph Diener; Ralph L Sacco; J Donald Easton; Christopher B Granger; Richard A Bernstein; Shinichiro Uchiyama; Jörg Kreuzer; Lisa Cronin; Daniel Cotton; Claudia Grauer; Martina Brueckmann; Marina Chernyatina; Geoffrey Donnan; José M Ferro; Martin Grond; Bernd Kallmünzer; Jerzy Krupinski; Byung-Chul Lee; Robin Lemmens; Jaime Masjuan; Miroslav Odinak; Jeffrey L Saver; Peter D Schellinger; Danilo Toni; Kazunori Toyoda Journal: N Engl J Med Date: 2019-05-16 Impact factor: 91.245
Authors: Scott E Kasner; Balakumar Swaminathan; Pablo Lavados; Mukul Sharma; Keith Muir; Roland Veltkamp; Sebastian F Ameriso; Matthias Endres; Helmi Lutsep; Steven R Messé; J David Spence; Krassen Nedeltechev; Kanjana Perera; Gustavo Santo; Veronica Olavarria; Arne Lindgren; Shrikant Bangdiwala; Ashkan Shoamanesh; Scott D Berkowitz; Hardi Mundl; Stuart J Connolly; Robert G Hart Journal: Lancet Neurol Date: 2018-09-28 Impact factor: 44.182
Authors: Robert G Hart; Mukul Sharma; Hardi Mundl; Scott E Kasner; Shrikant I Bangdiwala; Scott D Berkowitz; Balakumar Swaminathan; Pablo Lavados; Yongjun Wang; Yilong Wang; Antonio Davalos; Nikolay Shamalov; Robert Mikulik; Luis Cunha; Arne Lindgren; Antonio Arauz; Wilfried Lang; Anna Czlonkowska; Jens Eckstein; Rubens J Gagliardi; Pierre Amarenco; Sebastian F Ameriso; Turgut Tatlisumak; Roland Veltkamp; Graeme J Hankey; Danilo Toni; Daniel Bereczki; Shinichiro Uchiyama; George Ntaios; Byung-Woo Yoon; Raf Brouns; Matthias Endres; Keith W Muir; Natan Bornstein; Serefnur Ozturk; Martin J O'Donnell; Matthys M De Vries Basson; Guillaume Pare; Calin Pater; Bodo Kirsch; Patrick Sheridan; Gary Peters; Jeffrey I Weitz; W Frank Peacock; Ashkan Shoamanesh; Oscar R Benavente; Campbell Joyner; Ellison Themeles; Stuart J Connolly Journal: N Engl J Med Date: 2018-05-16 Impact factor: 91.245
Authors: Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly Journal: Lancet Neurol Date: 2014-04 Impact factor: 44.182